髄芽腫は、小児に最も多く見られる悪性脳腫瘍です。髄芽腫は、頭蓋骨の底部、脳幹のすぐ上にある小脳に発生することが定義されています。髄芽腫に関連する症状としては、朝に頭痛が起こり、日が経つにつれて改善すること、嘔吐を繰り返すこと、歩行困難や平衡感覚を失うことなどがあります。髄芽腫は、中枢神経系の他の部位に転移する可能性があります。治療には、化学療法、手術、生物学的療法、放射線療法などの選択肢があります。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Medulloblastoma - Overview
Medulloblastoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Medulloblastoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Medulloblastoma - Companies Involved in Therapeutics Development
Medulloblastoma - Drug Profiles
Medulloblastoma - Dormant Projects
Medulloblastoma - Discontinued Products
Medulloblastoma - Product Development Milestones
Featured News & Press Releases
Jun 21, 2022: Orphan Designation granted by EMA to MTX110 development for the treatment of Glioma
Jul 15, 2021: Abstract published in Neuro-Oncology demonstrates Curtana Pharmaceuticals' CT-179 prolonged event-free survival in an animal model of medulloblastoma
Dec 01, 2020: Moleculin announces FDA approves 3 rare pediatric disease designations for WP1066
Nov 11, 2020: ONC206 efficacy in brain tumors to be presented at 2020 SNO Conference
Aug 20, 2019: Moleculin announces CTRC approval of WP1066 pediatric brain tumor trial
Jun 11, 2018: Reviving the protector: new tactic against medulloblastoma
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Medulloblastoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Target, 2022 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Medulloblastoma - Dormant Projects, 2022
Medulloblastoma - Dormant Projects, 2022 (Contd..1)
Medulloblastoma - Discontinued Products, 2022
List of Figures
Number of Products under Development for Medulloblastoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
